

Rev03
 Update: Aug,08,2025

DATASHEET


CD30/TNFRSF8 hFc Chimera, Human

Cat. No.: Z04187


Product Introduction

Species	Human
Protein Construction	<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;"> CD30/TNFRSF8 (Phe19-Lys379) Accession # P28908-1 </div> <div style="background-color: #76923c; color: white; padding: 5px; text-align: center;"> hFc </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 5px;"> N-term C-term </div>
Purity	> 95% as determined by BisTris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Biological Activity	Measured by its binding ability in a functional ELISA. Immobilized Human CD30 Ligand, His Tag at 5µg/ml (100µl/well) on the plate can bind CD30/TNFRSF8 hFc Chimera, Human. Test result was comparable to standard batch
Expression System	HEK293
Theoretical Molecular Weight	65.2 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 80-115 kDa based on Bis-Tris PAGE result.
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.


Examples



CD30/TNFRSF8 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.



Immobilized Human CD30 Ligand, His Tag at 5 µg/ml (100 µL/well) on the plate. Dose response curve for CD30/TNFRSF8 hFc Chimera, Human, hFc Tag with the EC50 of 4.7 ng/ml determined by ELISA.



The purity of CD30/TNFRSF8 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

Background

Target Background : The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).

Synonyms : CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China